Physiomics PLC Appointment of part-time Head of Finance
03 May 2016 - 4:01PM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
03 May 2016
Physiomics plc
("Physiomics") or ("the Company")
Appointment of Anthony Clayden as part-time Head of Finance
The Company announces that Anthony Clayden, of Strategic Finance
Director Limited, has been appointed Head of Finance to lead the
financial management and provide company secretarial services with
effect from 1 May 2016. This is not a board position, and Anthony
is not being appointed a director or officer of Physiomics. At the
same time the existing Financial Controller and Company Secretary,
Liz King will step down from these duties but will remain available
to support a transition.
Anthony has broad experience advising on strategy and managing
the finance function in a variety of companies of differing size
and complexity. Anthony's career has encompassed advising a number
of businesses in the life sciences and healthcare sector. This
includes over 6 years as Chief Financial Officer and Company
Secretary of AIM quoted Futura Medical plc including preparation
for and IPO on AIM and a series of placings during his tenure.
Paul Harper commented "We are pleased to announce the addition
of Anthony to the senior management team with his AIM, sector and
financial experience. On behalf of the Board I wish to thank Liz
for her work at Physiomics and wish her well for the future."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (broker/nomad)
Katy Mitchell
+44 (0) 161 832 2174
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services
company applying simulations of cell behaviour to drug development
to reduce the high attrition rates of clinical trials. 80-90 per
cent of all clinical drug candidates fail to reach the market and
estimates show that an overall ten per cent improvement in success
rates could reduce the cost of one drug's development by as much as
$242 million, from the current estimate of around $800 million(1)
.
Physiomics develops computational systems biology models to
predict and understand cancer drug efficacy from pre-clinical
research to clinical development. Physiomics has created detailed
mathematical models incorporating the most important molecular
events taking place during the human cell cycle and apoptosis
processes. The company's SystemCell(R) technology enables the
simulation of populations of "virtual cells". The company has also
developed a "Virtual Tumour" model to simulate the effect of
anti-cancer drugs on tumour growth. The models are used to optimise
compound design and to design drug schedules and combination
therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and
floated on AIM in 2004. For further information, please visit
www.physiomics-plc.com
SystemCell(R) is a registered trademark of Physiomics plc
(1) Tufts Centre Impact Report 2002
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALIFVAETIFIIR
(END) Dow Jones Newswires
May 03, 2016 02:01 ET (06:01 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024